Henry Schein, Inc. $HSIC Shares Sold by IQ EQ FUND MANAGEMENT IRELAND Ltd

IQ EQ FUND MANAGEMENT IRELAND Ltd lowered its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 6.4% during the second quarter, Holdings Channel reports. The fund owned 12,545 shares of the company’s stock after selling 857 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Henry Schein were worth $916,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in HSIC. GAMMA Investing LLC boosted its stake in Henry Schein by 37.8% in the 1st quarter. GAMMA Investing LLC now owns 3,939 shares of the company’s stock worth $270,000 after buying an additional 1,081 shares during the last quarter. Teacher Retirement System of Texas acquired a new stake in Henry Schein in the 1st quarter worth about $3,293,000. Palisade Capital Management LP boosted its stake in Henry Schein by 16.7% in the 1st quarter. Palisade Capital Management LP now owns 44,163 shares of the company’s stock worth $3,025,000 after buying an additional 6,304 shares during the last quarter. OneDigital Investment Advisors LLC boosted its stake in Henry Schein by 22.5% in the 1st quarter. OneDigital Investment Advisors LLC now owns 4,917 shares of the company’s stock worth $337,000 after buying an additional 903 shares during the last quarter. Finally, IFM Investors Pty Ltd boosted its stake in Henry Schein by 6.6% in the 1st quarter. IFM Investors Pty Ltd now owns 23,831 shares of the company’s stock worth $1,737,000 after buying an additional 1,482 shares during the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on HSIC shares. Stifel Nicolaus reissued a “hold” rating and issued a $75.00 price target (down from $80.00) on shares of Henry Schein in a research note on Friday, July 25th. Robert W. Baird reaffirmed a “neutral” rating and issued a $72.00 price objective (down from $82.00) on shares of Henry Schein in a research note on Monday, July 14th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Henry Schein in a research note on Wednesday, October 8th. JPMorgan Chase & Co. reduced their price objective on Henry Schein from $80.00 to $76.00 and set an “overweight” rating on the stock in a research note on Thursday, August 7th. Finally, UBS Group reduced their price objective on Henry Schein from $75.00 to $70.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 6th. Five analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $76.67.

Henry Schein Stock Performance

Shares of NASDAQ:HSIC opened at $63.21 on Wednesday. The company has a market cap of $7.67 billion, a P/E ratio of 20.39, a PEG ratio of 2.10 and a beta of 0.81. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.78 and a current ratio of 1.41. Henry Schein, Inc. has a one year low of $60.56 and a one year high of $82.49. The business’s 50-day simple moving average is $66.56 and its 200 day simple moving average is $68.57.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, August 5th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.09). The company had revenue of $3.24 billion for the quarter, compared to analysts’ expectations of $3.22 billion. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The business’s quarterly revenue was up 3.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.23 earnings per share. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. On average, sell-side analysts forecast that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.